These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 23374976

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus.
    Arhin FF, Sarmiento I, Parr TR, Moeck G.
    Int J Antimicrob Agents; 2012 Feb; 39(2):159-62. PubMed ID: 22070858
    [Abstract] [Full Text] [Related]

  • 4. In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin.
    Vidaillac C, Parra-Ruiz J, Rybak MJ.
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):470-3. PubMed ID: 22018937
    [Abstract] [Full Text] [Related]

  • 5. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
    Belley A, Lalonde Seguin D, Arhin F, Moeck G.
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4342-5. PubMed ID: 27067327
    [Abstract] [Full Text] [Related]

  • 6. Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates.
    Campanile F, Borbone S, Perez M, Bongiorno D, Cafiso V, Bertuccio T, Purrello S, Nicolosi D, Scuderi C, Stefani S.
    Int J Antimicrob Agents; 2010 Nov; 36(5):415-9. PubMed ID: 20727722
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
    Saravolatz LD, Pawlak J, Johnson LB.
    Int J Antimicrob Agents; 2010 Jul; 36(1):69-72. PubMed ID: 20413274
    [Abstract] [Full Text] [Related]

  • 10. Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital.
    Vaudaux P, Huggler E, Arhin FF, Moeck G, Renzoni A, Lew DP.
    Int J Antimicrob Agents; 2009 Dec; 34(6):540-3. PubMed ID: 19744838
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN, Rybak MJ.
    J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.
    Karlowsky JA, Walkty AJ, Baxter MR, Adam HJ, Zhanel GG.
    Diagn Microbiol Infect Dis; 2014 Dec; 80(4):311-5. PubMed ID: 25294303
    [Abstract] [Full Text] [Related]

  • 14. Daptomycin non-susceptible, vancomycin intermediate methicillin-resistant Staphylococcus aureus ST398 from a chronic leg ulcer, Italy.
    Mammina C, Bonura C, di Carlo P, Calà C, Aleo A, Monastero R, Palma DM.
    Scand J Infect Dis; 2010 Dec; 42(11-12):955-7. PubMed ID: 20942775
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ.
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [Abstract] [Full Text] [Related]

  • 16. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).
    Leonard SN, Szeto YG, Zolotarev M, Grigoryan IV.
    Int J Antimicrob Agents; 2011 Jun; 37(6):558-61. PubMed ID: 21497067
    [Abstract] [Full Text] [Related]

  • 17. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
    Kelley PG, Gao W, Ward PB, Howden BP.
    J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies.
    Krause KM, Barriere SL, Kitt MM, Benton BM.
    Diagn Microbiol Infect Dis; 2010 Oct; 68(2):181-5. PubMed ID: 20846593
    [Abstract] [Full Text] [Related]

  • 19. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus.
    Gould IM.
    Int J Antimicrob Agents; 2008 Apr; 31 Suppl 2():1-9. PubMed ID: 18485997
    [Abstract] [Full Text] [Related]

  • 20. Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus.
    Arhin FF, McKay GA, Beaulieu S, Sarmiento I, Parr TR, Moeck G.
    Diagn Microbiol Infect Dis; 2009 Oct; 65(2):207-10. PubMed ID: 19748436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.